Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
AICAR
Free shipping on orders over €200
- If a product doesn't match the specification on its published COA, contact us with your batch number: we investigate against the lot's report and replace any product that fails it, at no cost to you.
- Contact us within 48 hours of delivery with photos of the outer box, inner packing, and any affected vials with labels legible. Confirmed transit damage is replaced at no cost to you.
3–7 days most of the EU · 10–14 Nordics/Baltics
Standard EU from €4.99 (RO) · core EU GLS €17.99 · Nordics/Baltics €12.99–€15.99 · Same-day dispatch before 14:00 CET on weekdays · Free shipping over €200.00 · no customs paperwork (EU) · via EU carrier network
€200.00 away from free shipping over €200.00. Under that, standard EU shipping is €17.99 (GLS, most of the EU).
How Paysera and SEPA work
- Pay: send a manual SEPA transfer using the IBAN we email you, or, where checkout offers it for your address, approve a SEPA transfer in your own bank via Paysera's hosted page.
- We confirm — Paysera notifies us instantly, or we match a manual transfer when it arrives (usually 1 business day).
- We dispatch — confirmed orders placed before 14:00 CET on a weekday typically ship the same day.
Card payments are not currently offered. There is no card processor on this checkout.
Research-grade AICAR. ≥98% supplier batch specification; selected lots independently tested (99.4% avg across published reports). Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €47.99 | €47.99 | -- |
| 3+ | €45.59 | €136.77 | 5% off |
| 5+Most Popular | €43.19 | €215.96 | 10% off |
| 10+ | €40.79 | €407.91 | 15% off |
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Published laboratory reports are available for selected lots. Check each report for its result and stated method. For research purposes only.
View report #233651 on janoshik.com →
24h dispatch, shipping from €4.99 in Romania, from €12.99 across the rest of Europe
Supplier batch specification on every product; independent Janoshik report on selected lots
About AICAR
AICAR (5-Aminoimidazole-4-carboxamide ribonucleoside, or acadesine) is an adenosine monophosphate (AMP) analogue that activates AMPK -- AMP-activated protein kinase, the cell's central energy sensor. When cellular energy is low (high AMP:ATP ratio), AMPK activates and triggers a suite of adaptive responses in research models: increased glucose uptake, enhanced fatty acid oxidation, suppression of energy-consuming biosynthetic pathways, and -- over time -- mitochondrial biogenesis. AICAR mimics energy depletion by being phosphorylated intracellularly to ZMP, which activates AMPK without actually reducing ATP.
AICAR's role in exercise mimetic research comes from the fact that AMPK activation recapitulates some of the metabolic adaptations of endurance exercise in research models. The compound was famously added to WADA's prohibited list in 2011 based on these properties, even before a validated detection method existed. In research, it serves as the standard pharmacological tool for studying AMPK-mediated metabolic pathways -- more selective and interpretable than AMP itself, which has broader and shorter-lived effects.
AICAR also has established cardioprotective effects in ischemia/reperfusion models and has been studied in oncology research for its effects on cancer cell metabolism. The hematological malignancy literature is particularly developed: AICAR induces apoptosis in certain leukemia and lymphoma cells through AMPK-dependent and -independent mechanisms.
Research Applications
AICAR is used as a standard AMPK activator for metabolic research, in exercise physiology and exercise mimetic studies, cardiac ischemia/reperfusion protection models, oncology metabolic research (particularly hematological malignancies), and as a comparator to other metabolic pathway activators like SLU-PP-332 and SR9009.
Specifications
| Parameter | Value |
|---|---|
| Compound | AICAR (5-Aminoimidazole-4-carboxamide ribonucleoside) |
| CAS Number | 2627-69-2 |
| Purity | ≥98% (supplier batch spec; 99.4% avg across independently tested lots) |
| Format | Lyophilized powder |
| Reconstitution | Sterile water or PBS |
| Storage | -20°C, protect from moisture |
Storage
Store at -20°C in a sealed container protected from moisture. AICAR is hygroscopic -- absorbs water from air. Keep desiccated. Reconstituted solutions are stable at 4°C for up to 1 week; longer-term, store aliquots at -20°C.
How does AICAR activate AMPK without reducing ATP?
AICAR is taken up by cells and phosphorylated by adenosine kinase to form ZMP (AICAR monophosphate). ZMP mimics AMP structurally and binds to the regulatory sites on AMPK that normally sense AMP, allosterically activating the kinase. Importantly, ZMP cannot be converted to ADP or ATP, so it accumulates and provides persistent AMPK activation without the cell actually running out of energy. This pharmacological mimicry is what makes AICAR a research tool -- it separates AMPK activation from the physiological context of energy depletion.
Why is AICAR banned in sports if it's a research compound?
WADA banned AICAR in 2011 because preclinical research, including well-publicized mouse studies, showed that AMPK activation improves endurance and activates exercise adaptation pathways in research models. The ban was preemptive -- before robust evidence of doping use or even a validated detection test existed. AICAR represents a category of compounds that WADA has increasingly banned based on pharmacological mechanism rather than documented performance enhancement in athletes. For research purposes, these substances remain important scientific tools studied for metabolic disease, cardiac protection, and oncology.
What is AICAR's relationship to the cancer research literature?
AICAR has a substantial cancer research literature, particularly for hematological malignancies. In chronic lymphocytic leukemia (CLL) and certain lymphoma models, AICAR induces apoptosis through mechanisms that include AMPK activation, but also through AMPK-independent effects on purine synthesis and DNA metabolism. The anti-proliferative effects in cancer cells relate to AICAR's ability to disrupt purine nucleotide synthesis (an essential nutrient for rapidly dividing cells) in addition to its AMPK-activating properties. This dual mechanism makes AICAR a useful tool for separating AMPK-dependent from metabolic effects in cancer biology research.
AICAR is supplied for laboratory research use only. Not approved for human use. Handle in compliance with institutional biosafety guidelines.
Specification Summary
About AICAR
AICAR (5-Aminoimidazole-4-carboxamide ribonucleoside, or acadesine) is an adenosine monophosphate (AMP) analogue that activates AMPK -- AMP-activated protein kinase, the cell's central energy sensor. When cellular energy is low (high AMP:ATP ratio), AMPK activates and triggers a suite of adaptive responses in research models: increased glucose uptake, enhanced fatty acid oxidation, suppression of energy-consuming biosynthetic pathways, and -- over time -- mitochondrial biogenesis. AICAR mimics energy depletion by being phosphorylated intracellularly to ZMP, which activates AMPK without actually reducing ATP.
AICAR's role in exercise mimetic research comes from the fact that AMPK activation recapitulates some of the metabolic adaptations of endurance exercise in research models. The compound was famously added to WADA's prohibited list in 2011 based on these properties, even before a validated detection method existed. In research, it serves as the standard pharmacological tool for studying AMPK-mediated metabolic pathways -- more selective and interpretable than AMP itself, which has broader and shorter-lived effects.
AICAR also has established cardioprotective effects in ischemia/reperfusion models and has been studied in oncology research for its effects on cancer cell metabolism. The hematological malignancy literature is particularly developed: AICAR induces apoptosis in certain leukemia and lymphoma cells through AMPK-dependent and -independent mechanisms.
Research Applications
AICAR is used as a standard AMPK activator for metabolic research, in exercise physiology and exercise mimetic studies, cardiac ischemia/reperfusion protection models, oncology metabolic research (particularly hematological malignancies), and as a comparator to other metabolic pathway activators like SLU-PP-332 and SR9009.
Specifications
| Parameter | Value |
|---|---|
| Compound | AICAR (5-Aminoimidazole-4-carboxamide ribonucleoside) |
| CAS Number | 2627-69-2 |
| Purity | ≥98% (supplier batch spec; 99.4% avg across independently tested lots) |
| Format | Lyophilized powder |
| Reconstitution | Sterile water or PBS |
| Storage | -20°C, protect from moisture |
Storage
Store at -20°C in a sealed container protected from moisture. AICAR is hygroscopic -- absorbs water from air. Keep desiccated. Reconstituted solutions are stable at 4°C for up to 1 week; longer-term, store aliquots at -20°C.
How does AICAR activate AMPK without reducing ATP?
AICAR is taken up by cells and phosphorylated by adenosine kinase to form ZMP (AICAR monophosphate). ZMP mimics AMP structurally and binds to the regulatory sites on AMPK that normally sense AMP, allosterically activating the kinase. Importantly, ZMP cannot be converted to ADP or ATP, so it accumulates and provides persistent AMPK activation without the cell actually running out of energy. This pharmacological mimicry is what makes AICAR a research tool -- it separates AMPK activation from the physiological context of energy depletion.
Why is AICAR banned in sports if it's a research compound?
WADA banned AICAR in 2011 because preclinical research, including well-publicized mouse studies, showed that AMPK activation improves endurance and activates exercise adaptation pathways in research models. The ban was preemptive -- before robust evidence of doping use or even a validated detection test existed. AICAR represents a category of compounds that WADA has increasingly banned based on pharmacological mechanism rather than documented performance enhancement in athletes. For research purposes, these substances remain important scientific tools studied for metabolic disease, cardiac protection, and oncology.
What is AICAR's relationship to the cancer research literature?
AICAR has a substantial cancer research literature, particularly for hematological malignancies. In chronic lymphocytic leukemia (CLL) and certain lymphoma models, AICAR induces apoptosis through mechanisms that include AMPK activation, but also through AMPK-independent effects on purine synthesis and DNA metabolism. The anti-proliferative effects in cancer cells relate to AICAR's ability to disrupt purine nucleotide synthesis (an essential nutrient for rapidly dividing cells) in addition to its AMPK-activating properties. This dual mechanism makes AICAR a useful tool for separating AMPK-dependent from metabolic effects in cancer biology research.
AICAR is supplied for laboratory research use only. Not approved for human use. Handle in compliance with institutional biosafety guidelines.
Related research reading
Objective comparisons and research guides covering this compound. Reference material for research use only.
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every vial label carries a code. Look it up on our Verify page: it shows what CertaPeptides publishes for that code and, for a withdrawn lot, that the lot was withdrawn and why. If yours is withdrawn, or if the code on your label finds nothing, email us that code.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland, Iceland). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with escalation to ANPC and alternative dispute resolution (SAL) available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
